Breaking News Instant updates and real-time market news.

CGBD

TCG BDC

$18.35

-0.18 (-0.97%)

, RDFN

Redfin

$26.33

0.81 (3.17%)

08:30
08/10/17
08/10
08:30
08/10/17
08:30

Three new option listings and one option delisting on August 10th

New option listings for August 10th include TCG BDC Inc (CGBD), Redfin Corporation (RDFN), and Reata Pharmaceuticals (RETA). Option delistings effective August 10th include Spectranetics Corp (SPNC).

CGBD

TCG BDC

$18.35

-0.18 (-0.97%)

RDFN

Redfin

$26.33

0.81 (3.17%)

RETA

Reata Pharmaceuticals

$28.09

-1.32 (-4.49%)

SPNC

Spectranetics

  • 26

    Sep

CGBD TCG BDC
$18.35

-0.18 (-0.97%)

07/10/17
JPMS
07/10/17
INITIATION
Target $19
JPMS
Overweight
TCG BDC initiated with an Overweight at JPMorgan
JPMorgan analyst Richard Shane started TCG BDC with an Overweight rating and $19 price target. The analyst believes the company has a "high quality" dividend with upside potential from higher interest rates.
07/10/17
WELS
07/10/17
INITIATION
Target $18.5
WELS
Outperform
TCG BDC initiated with an Outperform at Wells Fargo
Wells Fargo analyst Jonathan Bock started TCG BDC with an Outperform rating and $18.50 price target.
07/10/17
KBWI
07/10/17
INITIATION
Target $20
KBWI
Outperform
TCG BDC initiated with an Outperform at Keefe Bruyette
Keefe Bruyette analyst Ryan Lynch started TCG BDC with an Outperform rating and $20 price target.
RDFN Redfin
$26.33

0.81 (3.17%)

RETA Reata Pharmaceuticals
$28.09

-1.32 (-4.49%)

04/13/17
LTCO
04/13/17
INITIATION
Target $55
LTCO
Buy
Reata Pharmaceuticals initiated with a Buy at Ladenburg
Ladenburg analyst Matthew Kaplan initiated Reata Pharmaceuticals with a Buy and a $55 price target saying its lead program, bardoxolone methyl, is currently in Phase 3 development for the treatment of connective tissue disease-associated PAH. The analyst expects a strong readout for the CARDINAL study in 1H 2018 based on Phase 2 strength and expects approval in mid-2019. Additionally, REATA has orphan disease opportunities for omaveloxolone in Friedreich's ataxia and mitochondrial myopathy positioning the company to deliver highly differentiated products for attractive markets, the analyst wrote.
05/09/17
SBSH
05/09/17
NO CHANGE
Target $39
SBSH
Neutral
Reata Pharmaceuticals price target raised to $39 from $32 at Citi
Citi analyst Yigal Nochomovitz raised his price target for Reata Pharmaceuticals to $39 after re-analyzing the market size for pulmonary arterial hypertension patients in the U.S. The analyst raised his patient population estimate in the U.S. to 27,000 from 11,000 while lowering the peak share potential for Reata's PAH drug to 20% from 30%. Nochomovitz keeps a Buy rating on the shares.
07/24/17
PIPR
07/24/17
NO CHANGE
Target $60
PIPR
Overweight
Reata Pharmaceuticals price target raised to $60 from $53 at Piper Jaffray
07/25/17
SBSH
07/25/17
NO CHANGE
Target $87
SBSH
Buy
Reata Pharmaceuticals price target raised to $87 from $39 at Citi
Citi analyst Yigal Nochomovitz more than doubled his price target for shares of Reata Pharmaceuticals to $87 from $39. The clinical-stage biopharmaceutical company closed yesterday up $4.37, or 14%, to $35.47. The company yesterday reported "unexpected and highly impressive" results from a Phase 2 trial testing Bardoxolone in Alport Syndrome, Nochomovitz tells investors in a research note. The data suggest "very meaningful disease reversal," the analyst argues. He believes the planned Phase 3, with data expected in 2019, should work with at least a 60% probability. Nochomovitz keeps a Buy rating on Reata shares.
SPNC Spectranetics

07/25/17
RAJA
07/25/17
DOWNGRADE
RAJA
Market Perform
Spectranetics downgraded to Market Perform from Outperform at Raymond James
Raymond James analyst Jayson Bedford downgraded Spectranetics (SPNC) to Market Perform following the acquisition by Philips (PHG) for $38.50 per share and said another bidder is unlikely.
08/03/17
STFL
08/03/17
DOWNGRADE
STFL
Hold
Spectranetics downgraded to Hold from Buy at Stifel
Spectranetics (SPNC) is being acquired by Philips (PHG) for $38.50 per share.
08/04/17
NEED
08/04/17
DOWNGRADE
NEED
Hold
Spectranetics downgraded to Hold from Buy at Needham
Spectranetics (SPNC) is being acquired by Philips (PHG) for $38.50 per share.
08/04/17
GUGG
08/04/17
DOWNGRADE
GUGG
Neutral
Spectranetics downgraded to Neutral from Buy at Guggenheim
Spectranetics (SPNC) is being acquired by Philips (PHG) for $38.50 per share.

TODAY'S FREE FLY STORIES

PFE

Pfizer

$33.17

-0.19 (-0.57%)

13:30
08/17/17
08/17
13:30
08/17/17
13:30
Hot Stocks
Pfizer lymphoblastic leukemia treatment approved by FDA with boxed warning »

The FDA approved today…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Aug

  • 28

    Aug

  • 08

    Sep

  • 08

    Sep

  • 13

    Sep

WIN

Windstream

$2.01

0.11 (5.79%)

13:30
08/17/17
08/17
13:30
08/17/17
13:30
Options
Call buyers in Windstream as shares lose ground »

Call buyers in Windstream…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:30
08/17/17
08/17
13:30
08/17/17
13:30
General news
NY Fed's overnight reverse repo totaled $78.6 B with 30 counterparties »

NY Fed's overnight…

13:30
08/17/17
08/17
13:30
08/17/17
13:30
General news
Breaking General news story  »

Minneapolis Federal…

WERN

Werner

$30.95

-0.1 (-0.32%)

13:27
08/17/17
08/17
13:27
08/17/17
13:27
Hot Stocks
Werner CEO says business has been improving throughout the year »

The trucking firm's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

13:25
08/17/17
08/17
13:25
08/17/17
13:25
General news
U.S. VIX equity volatility surged 26% to 14.88 highs »

U.S. VIX equity…

13:25
08/17/17
08/17
13:25
08/17/17
13:25
Conference/Events
SEC holds a closed commission meeting »

Closed Commission Meeting…

WMT

Wal-Mart

$79.18

-1.7998 (-2.22%)

13:24
08/17/17
08/17
13:24
08/17/17
13:24
Recommendations
Wal-Mart analyst commentary  »

Wal-Mart posted good…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

  • 16

    Nov

  • 20

    Feb

ADP

ADP

$111.10

-0.48 (-0.43%)

13:21
08/17/17
08/17
13:21
08/17/17
13:21
Recommendations
ADP analyst commentary  »

ADP will have difficulty…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

  • 11

    Sep

NAK

Northern Dynasty

$1.56

0.065 (4.36%)

13:20
08/17/17
08/17
13:20
08/17/17
13:20
Options
Call buyers back in Northern Dynasty Minerals »

Call buyers back in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLS

Celestica

$11.55

-0.035 (-0.30%)

13:17
08/17/17
08/17
13:17
08/17/17
13:17
Upgrade
Celestica rating change  »

Follow-up: Celestica…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSRO

Tesaro

$112.99

-1.01 (-0.89%)

, AZN

AstraZeneca

$29.12

-0.0637 (-0.22%)

13:17
08/17/17
08/17
13:17
08/17/17
13:17
Hot Stocks
Breaking Hot Stocks news story on Tesaro, AstraZeneca »

Tesaro drops 2% after FDA…

TSRO

Tesaro

$112.99

-1.01 (-0.89%)

AZN

AstraZeneca

$29.12

-0.0637 (-0.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Sep

  • 08

    Sep

  • 08

    Sep

$NSD

NASDAQ Market Internals

13:17
08/17/17
08/17
13:17
08/17/17
13:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AZN

AstraZeneca

$29.11

-0.07 (-0.24%)

13:16
08/17/17
08/17
13:16
08/17/17
13:16
Hot Stocks
FDA posts approval of new dosage form for AstraZeneca's Lynparza 

Reference Link

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Sep

  • 08

    Sep

$NYE

NYSE Market Internals

13:16
08/17/17
08/17
13:16
08/17/17
13:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTL

CenturyLink

$19.72

-1.17 (-5.60%)

, LVLT

Level 3

$53.45

-1.73 (-3.14%)

13:13
08/17/17
08/17
13:13
08/17/17
13:13
Hot Stocks
CenturyLink says working to finalize Level 3 deal by end of Q3 »

CenturyLink (CTL) said in…

CTL

CenturyLink

$19.72

-1.17 (-5.60%)

LVLT

Level 3

$53.45

-1.73 (-3.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTL

CenturyLink

$19.73

-1.16 (-5.55%)

, LVLT

Level 3

$53.45

-1.73 (-3.14%)

13:12
08/17/17
08/17
13:12
08/17/17
13:12
Hot Stocks
Breaking Hot Stocks news story on CenturyLink, Level 3 »

CenturyLink says working…

CTL

CenturyLink

$19.73

-1.16 (-5.55%)

LVLT

Level 3

$53.45

-1.73 (-3.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADP

ADP

$111.10

-0.48 (-0.43%)

13:10
08/17/17
08/17
13:10
08/17/17
13:10
Options
ADP attracts put buyers as shares come under fire »

ADP attracts put buyers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Aug

  • 11

    Sep

ADOM

Adomani

$12.86

0.86 (7.17%)

, VLKAY

Volkswagen

$31.10

0.19 (0.61%)

13:06
08/17/17
08/17
13:06
08/17/17
13:06
Hot Stocks
Adomani sees $2.9B in settlement funds from Volkswagen »

Adomani (ADOM) announced…

ADOM

Adomani

$12.86

0.86 (7.17%)

VLKAY

Volkswagen

$31.10

0.19 (0.61%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HZNP

Horizon Pharma

$11.89

-0.05 (-0.42%)

13:05
08/17/17
08/17
13:05
08/17/17
13:05
Options
Horizon Pharma call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLS

Celestica

$11.50

-0.08 (-0.69%)

13:04
08/17/17
08/17
13:04
08/17/17
13:04
Upgrade
Celestica rating change  »

Celestica upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDVX

Medovex

$0.95

0.05 (5.56%)

12:55
08/17/17
08/17
12:55
08/17/17
12:55
Hot Stocks
Medovex names Charlie Farrahar as CFO »

Medovex reported it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFE

Pfizer

$33.20

-0.16 (-0.48%)

12:53
08/17/17
08/17
12:53
08/17/17
12:53
Hot Stocks
FDA posts approval of Pfizer's biologic license qpplication for Besponsa 

Reference Link

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Aug

  • 28

    Aug

  • 08

    Sep

  • 08

    Sep

  • 13

    Sep

NADL

North Atlantic Drilling

$1.44

-0.075 (-4.97%)

12:50
08/17/17
08/17
12:50
08/17/17
12:50
Options
Notable put spread in North Atlantic Drilling »

Notable put spread in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Aug

12:45
08/17/17
08/17
12:45
08/17/17
12:45
General news
Breaking General news story  »

Dallas Federal Reserve…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.